Transcept Pharmaceuticals, Inc.
News and overview for Transcept Pharmaceuticals, Inc.
Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter [Press Release]
PRNewswire | 1 minute ago
...PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. today announced that...NDA resubmission. Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical...Letter. Contact: Transcept Pharmaceuticals, Inc. Greg Mann Director...
Transcept Pharmaceuticals reports financial results for the third quarter of 2009
News-Medical.Net | 10 days 15 hours 21 minutes ago
Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience, today announced financial results for the three and nine months ended September 30, 2009.
USPTO issues Notice of Allowance for Transcept Pharmaceuticals' Intermezzo
News-Medical.Net | 19 days 8 hours 21 minutes ago
Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/833,323, which covers the use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate. Once issued, this patent will expire in February 2025.
Transcept Pharmaceuticals Receives Notice of Allowance for U.S. Patent Application on Intermezzo(R) [Press Release]
PRNewswire | 19 days 3 hours 34 minutes ago
...PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. today announced that...approval is received. Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical...R). CONTACT: Transcept Pharmaceuticals, Inc. Greg Mann Director...
Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17 [Press Release]
PRNewswire | 12 days 18 hours 34 minutes ago
...PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. today announced that...transcept.com Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical...com. Contact: Transcept Pharmaceuticals, Inc. Greg Mann Director...
Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12 [Press Release]
PRNewswire | 17 days 17 hours 5 minutes ago
...PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. , a specialty pharmaceutical...Passcode: 2918743. Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical...com. Contacts: Transcept Pharmaceuticals, Inc. Greg Mann Director...
Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application [Press Release]
PRNewswire | 25 days 11 hours 26 minutes ago
...Intermezzo(R). Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical...R). Contacts: Transcept Pharmaceuticals, Inc. The Ruth Group Greg...of TheRuth Group, for Transcept Pharmaceuticals, Inc.
Transcept Pharmaceuticals to Present at the BioCentury Thomson Reuters Newsmakers in the Biotech Industry Conference on September 16, 2009 [Press Release]
PRNewswire | 82 days 37 minutes ago
...PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. today announced that...transcept.com Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical...R). Contacts: Transcept Pharmaceuticals, Inc. The Ruth Group Greg...
Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results [Press Release]
PRNewswire | 101 days 10 hours 38 minutes ago
RICHMOND, Calif., Aug. 14 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc.
Transcept Pharmaceuticals to Present at Rodman & Renshaw and Baird Healthcare Investor Conferences on September 9 and September 10, 2009 [Press Release]
PRNewswire | 89 days 8 minutes ago
RICHMOND, Calif., Aug. 26 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc.
Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States [Press Release]
PRNewswire | 113 days 8 minutes ago
...Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement...Products L.P. and Transcept Pharmaceuticals, Inc. today announced entry...Intermezzo((R)). Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical...
Transcept Pharmaceuticals to Report Second Quarter 2009 Results [Press Release]
PRNewswire | 109 days 9 hours 6 minutes ago
...PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. , a specialty pharmaceutical...Intermezzo(R). Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical...R). Contacts: Transcept Pharmaceuticals, Inc. The Ruth Group Greg...
Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U.S. License and Collaboration Agreement [Press Release]
PRNewswire | 97 days 9 hours 38 minutes ago
...PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. today announced plans...Intermezzo((R)). Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical...by law. Contacts: Transcept Pharmaceuticals, Inc. The Ruth Group Greg...
Transcept Pharmaceuticals to Hold Conference Call on Agreement with Purdue Pharmaceutical Products L.P. to Commercialize Intermezzo(R) in the United States [Press Release]
PRNewswire | 113 days 8 minutes ago
...PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. will host a conference...Passcode: 5541799. Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical...transcept.com Contacts: Transcept Pharmaceuticals, Inc. Greg Mann Director...
Transcept Pharmaceuticals reports $3.8M loss in Q3
American City Business Journals | 10 days 21 hours 11 minutes ago
Transcept Pharmaceuticals Inc. lost $3.8 million in the September quarter.
Sign up for AdvaMed SmartBrief
Company Overview
| Company: | Transcept Pharmaceuticals, Inc. |
|---|---|
| Industry: | Drug Delivery Systems |
| Website: | http://www.transcept.com |
Transcept Pharmaceuticals may not make a bitter pill easier to swallow, but it'll make the pill more effective once it's inside. The company's drug delivery technology enhances absorption rates of active drug agents, reducing absorption times, as well as the time it takes for the drug to take effect. The company targets medications where rapid absorption would significantly benefit treatment, including central nervous system and psychiatric disorders. Lead product candidate Intermezzo offers a quick-acting, low-dosage medication for treating insomnia that occurs in the middle of the night. Transcept contracts with third parties for manufacturing and packaging. The company merged with publicly held Novacea in 2009.
Key Numbers
| Sales in U.S. Dollars (mil.) | 60.6 (2008) |
|---|---|
| One-year % Growth in Sales | 263.4 (2008) |
| Net Income in U.S. Dollars (mil.) | 34.8 (2008) |
| One-year % Growth in Net Income | 0.0 (2008) |
| Number of Employees | 33 (2008) |
| One-year % Growth in Number of Employees | -48.4 (2008) |
| Fiscal Year-End |